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Abstract
Background: Sacral chordoma (SC) is a neoplasm arising from residual notochordal cells degeneration. SC is
difficult to manage mainly because of anatomic location and tendency to extensive spread. Carbon ion
radiotherapy (CIRT) is highly precise to selectively deliver high biological effective dose to the tumor target
sparing the anatomical structure on its path even if when SC is contiguous to the intestine, and a surgical spacer
might be an advantageous tool to create a distance around the target volume allowing radical curative dose
delivery with a safe dose gradient to the surrounding organs. This paper describes a double approach—open
and hand-assisted laparoscopic—for a silicon spacer placement in patients affected by sacral chordoma undergoing
carbon ion radiotherapy.
Methods: Six consecutive patients have been enrolled for surgical spacer placement—open (three) or hand-assisted
(three)—prior carbon ion radiotherapy treatment in order to increase efficacy of carbon ion radiotherapy minimizing its
side effects.
Results: Results showed that silicon spacer placement for SC treatment is feasible both via laparoscopic and laparotomic
approach.
Conclusions: Its use might improve CIRT safety and thus efficacy for SC treatment.
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Background
Worldwide, with an amount of 1–4 % of all malignant
bone tumors, sacral chordoma (SC) is a rare neoplasm
belonging to the family of chordomas, a type of tumor
arising through malignant transformation of benignant
residual notochordal cells that could hypothetically arise
from all the length way of the skeletal neuraxis [1]. SC
represents around 30 % of all chordomas locations [2]
with a commonly slow-growing, chemo/radioresistant,
and locally destructive behavior [3]. Hitherto, the
achievement of R0 margin after surgical resection is the
primary prognostic factor influencing local control. The
mortality related to SC is nearly invariable due to their
local unrestrainable progression, their common local re-
currence (ranging from 43 to 85 % [4]) after surgical re-
section, and finally, to their very poor sensitivity to any
chemotherapy [5] and conventional photon-based radio-
therapy (RT) [6].
Carbon ion radiotherapy (CIRT) has recently emerged
as very promising strategy for unresectable SC [7].
Charged particles (carbon ions and protons) provide su-
perior dose distribution to non-surface tumors com-
pared with photon RT due to their unique physical
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properties. In particular, when penetrating the body,
their peculiarity compared to photon and proton RT is
the release of low radiation dose along their travel path,
except for the maximum energy at the end of their range
(Bragg peak), with no dose beyond that. This pattern al-
lows to selectively irradiate the tumor target by sparing
the surrounding normal tissues. Furthermore, biological
experiments in vitro cell line models have shown the
higher tumoricidal potential and thus higher biological
effectiveness of carbon ion beams compared to the other
beam qualities, possibly responsible for the promising
results in different SC patient series [8].
The National Center for Oncological Hadrontherapy
(CNAO) is the first center in Italy and second in
Europe to have started for cancer patient treatment
with a dual beam (proton and carbon ions) particle
therapy equipment.
High doses are required in the curative RT setting for
SC patients. The large and small intestines are very sus-
ceptible to radiation dose in general, with surgical adhe-
sions or gastrointestinal bleeding or intestinal perforations
[9] as major side effects when escalating the dose to the
target. Gastroenteric toxicity after RT can represent a dra-
matic negative prognostic factor immediately or in case of
new abdominal surgeries. In case of CIRT, these effects
have been reported to be related to the smooth muscle
layer radiation response with coagulation necrosis, arterial
thrombosis, and atrophy of the intestinal epithelium [10].
The contiguity of radiosensitive organs to the CIRT tumor
target in particular anatomical conditions might represent
an important dose-limiting factor for CIRT. In both CIRT
and conventional RT, anatomical spacer insertion has
been reported to be a procedure to safely increase deliv-
ered dose to the tumor target and thus reach high doses
to ensure adequate tumor control. Several methods or de-
vices have already been reported to be used to locally dis-
place the bowel loops or the rectum from the radiation
field to reduce bowel and rectal complications and in-
crease the total delivered radiation dose [11], especially for
prostate cancer treatment with both conventional RT [12]
and CIRT [13].
The aim of the current study is to analyze the feasi-
bility of the insertion of a newly customized spacer
prior CIRT in SC patients by laparotomic or hand-
assisted laparoscopic approach, in terms of procedure
validation and patient tolerance. Furthermore, the ad-
vantage in CIRT dose distribution due to our spacer
silicon insertion is shown by comparing different
treatment plans on CT scans from the same SC pa-
tient enrolled in the study, performed both before
and after spacer insertion. This dosimetric advantage
might translate in lower incidence of the digestive
tract acute and late CIRT-related toxicity during pa-
tient treatment and subsequent follow-up.
Methods
Experimental study design and patient selection
Since 2014 to 2015, six consecutive patients were en-
rolled in the present study at San Matteo Hospital –
Dept. of General Surgery among SC patients eligible for
CIRT at CNAO. Patient characteristics and follow-up
(up to 20 months) are presented in Table 1. This study
is an experimental, exploratory, single-arm study ap-
proved by the Ethical Committee of the San Matteo
Hospital and performed in accordance with the ethical
standards of the Declaration of Helsinki. Specific written
consent was obtained from all participants and data
were anonymized. Exclusion criteria to enter the surgical
study were principally related to chordomas anatomical
position (below S3 was considered not eligible), tech-
nical contraindication to laparoscopic/open spacer posi-
tioning and patient general conditions allowing major
surgery. Moreover, all the patients were considered eli-
gible with a distance between the rectum and tumor in-
ferior of 5 mm measured by preoperative CT scan and
MRI. According to these exclusion characteristics, 14 pa-
tients have been ruled out and directly considered suit-
able for CIRT treatment. Patients who received previous
abdominal surgery were selected for laparotomic ap-
proach due the high possibility of adhesions whereas pa-
tients that never underwent abdominal surgeries before
were selected for hand-assisted laparoscopic surgery.
After surgical spacer placement, SC patients were
treated at CNAO within a phase II protocol for CIRT of
bone and soft tissue sarcomas of the trunk approved by
the institutional ethics committee of CNAO and autho-
rized by the Ministry of Health. SC patients meeting all
the following eligibility criteria were enrolled for CIRT at
CNAO: no distant metastasis at the initial referral for
treatment, no previous RT at the same site, a Karnofsky
Table 1 Patients characteristics
Variable Patient (6)
Gender
Male 2 pts (33.3 %)
Female 4 pts (66.6 %)
Age (median range) 45.3 years (20–55 years)
Follow-up 13.3 (6–18 months)
Previous abdominal surgery
- Yes 3 pts (50 %)
Time of surgery—open
approach (min)
133.33 (mean) – max 200/min 75
Post operative day (POD) of stay 7.66 (mean) – max 9/min 6
- No 3 pts (50 %)
Time of surgery—laparoscopic
approach (min)
150 (mean) – max 240/min 70
Post operative day (POD) of stay 10 (mean) – max 12/min 9
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PS score >60, and a grossly measurable tumor. CIRT
feasibility and optimal CIRT delivery are always dis-
cussed within CNAO clinical meeting within a board of
radiation oncologists, radiologists, physicists, and sur-
geons. In case pre-enrollment patient CT or MRI shows
chordoma located in close vicinity to the rectal wall or
the bowel loop, the feasibility of spacer insertion and en-
rollment in the present collaborative study is routinely
discussed.
CIRT at CNAO
The specific technique of CIRT used at CNAO has been
previously described in details [14]. For treatment plan
preparation, CT and MRI data sets taken during the
simulation phase were rigidly co-registered using the
treatment planning system (TPS) (Syngo VC13, Siemens,
Germany) to delineate the macroscopic tumor as the
gross tumor volume (GTV), and the geometrical expan-
sion of the GTV with its potential microscopic extension
as the clinical target volume (CTV). A 4-mm expansion
to the CTV was used to generate the planning target
volume (PTV). The dose prescribed to the PTV (carbon
physical dose in Gray × relative biologic effectiveness
[RBE]) was 70.4 Gy (RBE) in 16 fractions of 4.4 Gy
(RBE) each, 4 days a week on the basis of the results
from the previous experience on CIRT trials of bone and
soft tissue tumors adapted to CNAO clinical equipment
[15]. RBE is variable depending on many factors incor-
porated into TPS (LEM I). Preclinical studies were per-
formed in CNAO to assess the optimal dose prescription
[16]. Normal structures were contoured for treatment
planning (skin, intestine, rectum, sigma, bladder, cauda,
and nerve roots), and dose constraints adopted as de-
fined in previous clinical trials [7]. The CTV received at
least 90 % of the prescribed dose. The modality of pa-
tient treatment and component system used for ensuring
reproducibility of the patient setup position has been
already described [17]. At the end of the CIRT course,
the patients were closely monitored through physical ex-
aminations and MRI. Subsequent follow-up visits to
check the progress of SC patients were performed in
CNAO at least every 3 months. CIRT toxicity during
treatment and at each follow-up is routinely scored by
means of the Common Terminology Criteria for Ad-
verse Events (CTCAE) v4.0 scale.
Silicon spacer preclinical assessment for radiation
hardness and stability
Prior to the clinical use of the spacer, several measure-
ments were performed to evaluate its physical stability
during and after CIRT, as well as its main properties po-
tentially affecting clinical protocols for CIRT when ex-
posed to particle beams. Firstly, high-energy scanned
carbon ion beams (208.6 MeV/u) produced by the
CNAO synchrotron were used to expose a spacer sam-
ple, consisting of five overlapping sheets of material (1.1-
mm thick each, 10 × 5 cm2 area, closely simulating the
spacer intended to use in the clinical setup) to a single
dose of 135 Gy, much exceeding the therapeutic dose
level, on a 3 × 3 cm2 portion of the spacer. Then, mea-
surements of the particle range in the spacer material
were performed at the carbon ion beam energy of
280 MeV/u using the Peakfinder dedicated device
(PTW, Freiburg, Germany), in terms of water equivalent
path length (WEPL) [18]. Finally, the spacer underwent
computed tomography (CT) scan, acquired using the
head protocol adopted for planning CT scans in the clin-
ical routine at CNAO (120 kVp, 320 mAS, 2 mm thick-
ness, H31s reconstruction filter, 500 mm field of view).
Silicon sheet spacer modeling
For each patient, silicone spacer was shaped according
to pre- and intraoperative findings from a 10 × 10 cm
silicone sheet with a width of 1 mm (Distrex, Padua,
Italy). From one sheet, it was possible to obtain up to six
surgical spacers, for a total of 6-mm thickness. Con-
toured spacers were then simply fixed all together by
Prolene suture (Fig. 1). This procedure allowed the sur-
geon to decide the desired final width of the spacer
based on patient anatomical features. For the spacer de-
sign, we decided to use silicone rubber as material for its
biocompatibility, temperature, and chemical resistance
other than mechanical properties. Biocompatibility, de-
fined as “the ability of a material to perform its function
with an appropriate host response in a specific situation”
[19], perfectly mirrors the main quality of this material
with a nonirritating and nonsensitizing behavior inside
the body, after its placement. Mechanical quality is an
additional important feature of this polymer ensuring a
high tear and tensile strength, up to 250 ppi and
1500 psi, respectively [20]. Silicone’s intrinsic features,
such as tenderness and flexibility, have been considered
adequate for the appropriate accommodation of the spa-
cer on the tumor bulge.
Surgical procedure
For the surgical procedure, all the patients underwent
general anesthesia with tracheal intubation, indwelling
bladder catheter and were placed in a decubitus dorsal
position with their arms next to their body. At the time
anesthesia was induced, intravenous antibiotic prophy-
laxis with first-generation cephalosporin was established.
For laparotomic procedures, an umbilical/pubic mid-
line laparotomy was performed with direct access to the
abdominal cavity.
For laparoscopic procedures, trocars and hand-assisted
device were placed as follows. Two 10 mm optical tro-
cars were placed in the subumbilical region and in the
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right lower quadrant (right iliac fossa), respectively. The
hand-assisted device was placed at the level of the left
rectus border (Fig. 2). Insufflation into the abdominal
cavity with carbon gas, reaching a maximum abdominal
pressure of 15 mmHg was performed. After the pneu-
moperitoneum was achieved, a 10 mm 30° optic was in-
troduced inside the abdominal cavity through the
umbilical trocar.
Trendelenburg position was achieved in order to dis-
locate intestinal loops for both.
In both surgical setup (open or laparoscopic), a retro-
rectal pouch was created by blunt dissection of parietal
peritoneum and the spacer was then inserted and fixed
with Ethilon 3/0 just rebuilding the peritoneum pouch.
Results
Silicon spacer preclinical assessment for radiation
hardness and stability
Visual inspection after the irradiation and 1 month later
did not reveal any macroscopical differences between
the spacer at the level of exposed and unexposed areas,
in terms of sample transparency and color, nor any vari-
ation to the tactile or heating effect. The same WEPL
value, equal to 1.084, was measured within both previ-
ously exposed and unexposed portions of the spacer. Fi-
nally, the difference between the mean Hounsfield units
(HU) calculated within the irradiated and non-irradiated
areas fell well within the statistical noise (418 ± 7 as one
standard deviation versus 416 ± 8), thus showing no
radiation-induced variation in the x-ray attenuation
properties (i.e., electron density) of the investigated
material.
Patient workout and surgical procedure
According to eligible criteria, a series of six patients
were enrolled in this study. Three patients underwent
open surgical spacer insertion whereas the other three
hand-assisted laparoscopic positioning. All the patients
underwent silicon spacer placement without any intra-
operative complications. Laparotomic and laparoscopic
spacer placement showed different advantages princi-
pally secondary to patient characteristics. Laparotomic
surgery has been used for patients who underwent previ-
ous abdominal surgeries in order to by-pass adhesions
presence. For patients who face abdominal surgery for
the first time, laparoscopic approach was preferred.
Compared to laparotomic approach, hand-assisted lapar-
oscopy allowed surgeons direct hand contact with the
operative field, maximizing tactile feedback and minim-
izing surgical injury. Silicone spacer placement demon-
strated to be safe for the patients during treatment and
for the entire follow-up period of time. Mean postopera-
tive days (mPOD) before CIRT were 7.66 ± 1.24 for the
patients who underwent open approach and 10 ± 1.41
Fig. 1 Shaping and preparation of patient-tailored silicone spacer. Starting from a single, 1-mm width and 10 × 10 cm silicone sheet (a), the first
plate has been created and shaped directly from tumor features (b) with surgical blade. Subsequently, the optimal width for the final spacer has
been chosen (usually around 5 mm) and then singles pre-modeled silicone sheets (c) are stacked up and fixed by 1-0 Prolene suture (d–f)
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for the others undertaking the laparoscopic method. For
the present study, all patients CT and MRI during and
after CIRT were reviewed in order to assess any pros-
thesis displacement or any other anatomic changes. Dur-
ing CIRT, the presence of the spacer keeps digestive
tract far away from the irradiated area; thus, the radi-
ation field is unaffected by rectum filling or intestine
movement (Fig. 3a). Patient imaging did not show ana-
tomic variations, and silicone spacer placement has been
demonstrated to be safe for the patients for the entire
follow-up period of time. Patient enrolled in the study
did not show any gastrointestinal toxicity during CIRT
or at follow-up, such as gastrointestinal bleeding, fecal
urgency, or lower abdominal cramping (median follow-
up time 13.3 months, range 6–18 months). Any spacer
dislocation has been observed during the follow-up
period.
Laparotomic representative case
Under general anesthesia, an umbilical/pubic laparotomy
was performed with direct access to the abdominal cavity
that was then manually explored with SC identification.
Trendelenburg position was then achieved. After identifi-
cation of the iliac vessels, the ureter and the gonadic ves-
sels, the peritoneum was bluntly dissected at the tumor
level. The ureter was gently isolated, and the peritoneum
was detached from the tumor to create the appropriate
zone for the spacer positioning. Up to six silicon sheets
(1 mm of width each) were shaped to perfectly fit the cre-
ated area between the parietal peritoneum and chordoma
surface. Silicon spacer was then located, and the periton-
eum was closed on it by continue Vicryl suture (Vicryl 3/
0). No other surgical procedures were needed in order to
secure the device. The abdomen was then closed by ana-
tomical layers.
Laparoscopic representative case
Under general anesthesia, the patient was fixed to the
table and laparoscopic trocars were positioned as fol-
lows: the first 12-mm port (Fig. 2a) for the laparoscope
was placed at the umbilical site, the second (Fig. 2b) 10-
mm was placed at the right side of the rectus muscle,
Fig. 2 Laparoscopic hand-assisted silicone spacer placement. The peritoneum has been dissected directly above of the tumor area intended to
dress through the spacer (a, b). The molded spacer has been located inside the created “peritoneal pouch” and then fastened by continue 3-0
Prolene suture (c–e). The conclusion of peritoneal closure ensures the optimal fixation and stability of the silicone spacer (f)
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and finally, the GelPort device, after a 6.5-cm length skin
incision, was sited at the left side of the rectal muscle
(Fig. 2c). The iliac vessels, the ureter, and the gonadic
vessels were identified, and the peritoneum covering the
tumor was dissected preparing a “peritoneal pouch”. Fi-
nally, the silicon-based spacer was customized to fit on
it. Silicon spacer was then located, and the peritoneum
was closed on it by continue Vicryl suture. Laparoscopic
and GelPort accesses were then closed.
CIRT plans comparison
In order to show the effect of the spacer insertion on
CIRT planning, we selected one of the six patients
enrolled in our study to perform the same CIRT plan
recalculation on a CT from the same patient but
undertaken before the silicon spacer insertion. In
Fig. 3a, representative CT slices from the two CIRT
plans show how the spacer insertion allows separation
of the rectal wall from the irradiated area, with in-
creasing of the tumor coverage with the maximum
prescribed curative dose. Furthermore, a comparison
of dose volume histograms (DVH) from the two plans
(Fig. 3b) shows little effect on the tumor coverage but
great sparing of the rectum and intestine in case of
spacer insertion.
Discussion
Beyond histological confirmation, surgical treatment is
still quoted as the standard cure management for SC
[21]. Surgical radical resection offers a more extended
disease-free period compared to R1 resection, but often
this treatment cannot be achieved due to the chordoma
Fig. 3 Plan comparison study on different CT from the same patient selected for spacer positioning at CNAO. a Different CIRT plans depicted on
axial images at the same anatomical level for the same chordoma patient. Red lines for GTV and green lines for CTV are included within the
prescription dose isodose in both CIRT plans of 70.4 Gy (RBE). In the upper panel, the digestive area (rectal wall in green and intestine in blue) is
contiguous to the prescribed dose isodose. In the lower panel, the digestive tract is far away from irradiated area due to the spacer (pointed by a
red arrow). b Comparison of DVH for GTV (red), PTV (pink), and digestive tract (rectum green, intestine blue) dose coverage from the two CIRT
plans compared in a. Coverage of the tumor is higher with the spacer CIRT plan (dotted lines) compared to the plan without it (continuous lines).
With the CIRT spacer, plan dose sparing to the digestive tract is achieved
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volume at the time of diagnosis [22] and to the possible
involvement of the upper levels of the sacrum or the
lumbar spine [23]. As of now, sacrectomy with R0 resec-
tion margins offers the best long-term prognosis [24]
even with its aggressiveness and the deriving low quality
of life with an overall 5 and 10-year survival rates of 45–
77 and 28–50 %, respectively [25]. Most important
limitative surgical outcomes are urinary and bowel in-
continence [21], wound infections, chronic neuropatic
pain, and paresis.
The consensus meeting of 2013 on chordomas or-
ganized by the European Society for Medical Oncol-
ogy (ESMO) established that surgery and high-dose
RT are the treatment mainstays for localized chordo-
mas, both of which have curative potentials [26]. For
SC patients, CIRT represents an innovative and useful
weapon, which is worthy to be further investigated
[27] within controlled clinical studies. SC is character-
ized by very poor radiosensitivity to “standard” pho-
ton RT, but carbon ion and protons RT allow
delivering high conformal dose to the tumor due to
their intrinsic physical properties increasing the cura-
tive potential of the RT treatment course. Moreover,
as deeply reviewed by Durante M., carbon ion beams
(similar to the other members of the heavy ions fam-
ily) deliver a high-conformed energy into the treat-
ment area combined with a greater radiobiological
effectiveness [28], thus increasing the tumoricidal ef-
fect probability. Main injuries to the small and large
intestines due to RT are related to fibrosis and vascu-
lar insufficiency resulting in a status of chronic ische-
mia [29]. This condition can then lead to chief
problems such as intestinal obstruction, severe bleed-
ing, or fistula formation all the length way of the in-
testine even if with distinctions between the terminal
ileum, cecum, sigmoid, and rectum [30]. Undoubtedly,
the greatest concern regarding the application of
CIRT for the treatment of tumor target localized in
the abdomen remains gastro-urinary tract (GUT) tox-
icity. In particular, the proximity of SC to the sigma-
rectum tract forces the radiation oncologist to reduce
the tumor dose coverage in the tumor area closed to
the GUT critical organs, limiting the curative poten-
tial of the delivered treatment. With our study and
CIRT plans comparison, we have shown that our sili-
con spacer insertion might help in delivering high
curative doses to the SC sparing the GUT critical or-
gans. Evaluations and instrumental measurements per-
formed on the spacer, prior its implantation, showed
that the spacer is not affected by radiation damage
when exposed even to high doses of ion beams and
therefore can be safely used in the clinical practice to
help sparing healthy tissues from unwanted high
doses during CIRT.
From urological and gynecologic experience deriving
from RT for several tumoral diseases, different ap-
proaches have been used to displace the intestine out-
side the irradiation-targeted area [31]. We believe that
the design and positioning of a spacer represents the
solution deliver safe CIRT for SC patients, and, in
particular our spacer might be a valuable tool to sep-
arate the RT-targeted tumor volume from the bowel
loop. We also consider our findings very helpful not
only for CIRT but also for conventional 3D-conformal
RT where high radiation doses are delivered with
curative intent to tumor targets in the abdomen. To
our knowledge of the literature, the number of cases
presented in the present work is the largest ever pub-
lished by a single center using silicon spacers, and
represents the first report using the minimally inva-
sive technique (in three out of six cases) for silicon
spacer placement prior CIRT for SC. Mima et al. de-
scribed 17 cases of laparotomic polytetrafluoroethyl-
ene (PTFE) spacer placement with good results [22].
We considered to use silicon instead of PTFE for
three reasons: (a) silicon is a biocompatible material
worldwide used for surgical implants; (b) the cost ef-
fectiveness of silicon is superior to PTFE (the com-
mercial price of silicon a sheet is 6/10 times less
compare to PTFE); and (c) we found silicon superior
to PTFE in terms of modeling and customization to
the anatomy of the patient. Analyzing our experi-
ence, we can state that the use of a silicon spacer
adapted to the anatomical features of the SC is safe
and feasible, without any complications neither intra
nor postoperative. The hand-assisted minimally inva-
sive technique has been feasible and safe by ensuring
correct positioning of the spacer, and we chose the
open technique in cases of previous abdominal
surgery because of possible peritoneal adhesions.
Hand-assisted laparoscopy provided optimal tissue
palpation and retraction, tactile feedback, 3-D spatial
orientation, and blunt dissection of the involved ana-
tomical structures. The use of the non-dominant
hand directly into the operative field played a pivotal
role for the choice of this unique minimally invasive
approach that combined the finest aspects of the
“classical” open surgery with those of conventional
laparoscopy.
Conclusions
Our preliminary clinical study shows how surgical spacer
placement before CIRT could be a feasible approach
to achieve a patient-tailored treatment minimizing
RT-related toxicity. Shaping of the spacer, directly
modeled on the anatomical feature of the patient, al-
lows to produce patient-specific tailored device. The
overall safety of the spacer seemed to be excellent
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with a 100 % successful rate whereas no adverse ef-
fects were noticed in any patient treated. Spacer posi-
tioning increases the distance between chordoma and
the most critical organs at risk reducing at the same
time their exposure to CIRT and, therefore, the prob-
ability of any hazardous toxicity during and after
therapy.
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